Gene · 54890
Papers4,144
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
761 to 780 of 4,144
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Activation of M1 Macrophages is Associated with the JNK-m6A-p38 Axis in Chronic Obstructive Pulmonary Disease. | Int J Chron Obstruct Pulmon Dis | 2023 | 37822331 | PubTator, text mining | PubMed |
| Single-cell sequencing technology applied to epigenetics for the study of tumor heterogeneity. | Clin Epigenetics | 2023 | 37821906 | PubTator, text mining | PubMed |
| Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics. | Cancer Cell Int | 2023 | 37821870 | PubTator, text mining | PubMed |
| N6-methyladenosine in 7SK small nuclear RNA underlies RNA polymerase II transcription regulation. | Mol Cell | 2023 | 37820733 | PubTator, text mining | PubMed |
| METTL3-Mediated RNA m6A Modification Regulates the Angiogenic Behaviors of Retinal Endothelial Cells by Methylating MMP2 and TIE2. | Invest Ophthalmol Vis Sci | 2023 | 37819742 | PubTator, text mining | PubMed |
| Construction of a Prognostic Model Based on Methylation-Related Genes in Patients with Colon Adenocarcinoma. | Cancer Manag Res | 2023 | 37818334 | PubTator, text mining | PubMed |
| Hypoxia-induced m6A demethylase ALKBH5 promotes ovarian cancer tumorigenicity by decreasing methylation of the lncRNA RMRP. | Am J Cancer Res | 2023 | 37818080 | PubTator, text mining | PubMed |
| CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. | Nat Commun | 2023 | 37816727 | PubTator, text mining | PubMed |
| IGF2BP2 acts as a m6A modification regulator in laryngeal squamous cell carcinoma through facilitating CDK6 mRNA stabilization. | Cell Death Discov | 2023 | 37816718 | PubTator, text mining | PubMed |
| The predictive significance of a 5-m6A RNA methylation regulator signature in colorectal cancer. | Heliyon | 2023 | 37810844 | PubTator, text mining | PubMed |
| Remimazolam relieved the injury of hypoxia/reperfusion treated human embryo liver cell line through the targeting METTL3 mediated m6A modification of P53. | Heliyon | 2023 | 37809663 | PubTator, text mining | PubMed |
| The m6A reader YTHDC1-mediated lncRNA CTBP1-AS2 m6A modification accelerates cholangiocarcinoma progression. | Heliyon | 2023 | 37809459 | PubTator, text mining | PubMed |
| N6-methyladenosine methyltransferase KIAA1429 promoted ovarian cancer aerobic glycolysis and progression through enhancing ENO1 expression. | Biol Direct | 2023 | 37807062 | PubTator, text mining | PubMed |
| Association between ankylosing spondylitis and m6A methylation. | J Orthop Surg Res | 2023 | 37805597 | PubTator, text mining | PubMed |
| Emerging roles of RNA binding proteins in intervertebral disc degeneration and osteoarthritis. | Orthop Surg | 2023 | 37803912 | PubTator, text mining | PubMed |
| YTHDF2 facilitates aggresome formation via UPF1 in an m6A-independent manner. | Nat Commun | 2023 | 37803021 | PubTator, text mining | PubMed |
| Loss of YTHDF2 Alters the Expression of m6A-Modified Myzap and Causes Adverse Cardiac Remodeling. | JACC Basic Transl Sci | 2023 | 37791304 | PubTator, text mining | PubMed |
| STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis. | Int J Med Sci | 2023 | 37790851 | PubTator, text mining | PubMed |
| M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics. | Arthritis Res Ther | 2023 | 37784134 | PubTator, text mining | PubMed |
| Identification of novel lactate metabolism-related lncRNAs with prognostic value for bladder cancer. | Front Pharmacol | 2023 | 37781694 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54890/papers?page=39